The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 11, 2006
Filed:
Sep. 19, 2003
Chen Chen, San Diego, CA (US);
Thomas R Webb, Olivenhain, CA (US);
James R Mccarthy, Zionsville, IN (US);
Terence Moran, San Diego, CA (US);
Keith M Wilcoxen, San Diego, CA (US);
Charles Q Huang, San Diego, CA (US);
Chen Chen, San Diego, CA (US);
Thomas R Webb, Olivenhain, CA (US);
James R McCarthy, Zionsville, IN (US);
Terence Moran, San Diego, CA (US);
Keith M Wilcoxen, San Diego, CA (US);
Charles Q Huang, San Diego, CA (US);
Neurocrine Biosciences, Inc., San Diego, CA (US);
Abstract
This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein Ris NRRor OR; Ris Calkyl, Calkyloxy or Calkylthio; Ris hydrogen, Calkyl, Calkylsulfonyl, Calkylsulfoxy or Calkylthio; Ris hydrogen, Calkyl, mono- or di(Ccycloalkyl)methyl, Ccycloalkyl, Calkenyl, hydroxyCalkyl, CalkylcarbonyloxyCalkyl or CalkyloxyCalkyl; Ris Calkyl, mono- or di(Ccycloalkyl)methyl, ACH, CalkyloxyCalkyl, hydroxyCalkyl, Calkenyl, thienylmethyl, furanylmethyl, CalkylthioCalkyl, morpholinyl, mono- or di(Calkyl)aminoCalkyl, di(Calkyl)amino, CalkylcarbonylCalkyl, Calkyl substituted with imidazolyl; or a radical of formula —Alk—O—CO—Ar; or Rand Rtaken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).